Table 1. The characteristics of the ADNI subjects at baseline.
| Characteristics | NC | MCI | AD | P* | |||
|---|---|---|---|---|---|---|---|
| Age (years) | 281 | 74.51 ± 5.56 | 483 | 72.28 ± 7.45 | 48 | 75.51 ± 9.23 | <0.01 |
| Gender (male/female) | 281 | 136/145 | 483 | 282/201 | 48 | 30/18 | 0.02 |
| Education (years) | 281 | 16.41 ± 2.66 | 483 | 15.98 ± 2.82 | 48 | 15.73 ± 2.62 | 0.08 |
| APOE ε4 (0/1/2) | 281 | 204/70/7 | 483 | 262/180/41 | 48 | 14/25/9 | <0.01 |
| CDR-SB | 207 | 0.03 ± 0.13 | 406 | 1.44 ± 0.87 | 47 | 4.44 ± 1.69 | <0.01 |
| MMSE | 281 | 29.07 ± 1.15 | 483 | 27.89 ± 1.69 | 48 | 22.96 ± 2.03 | <0.01 |
| ADAS-cog | 281 | 9.06 ± 4.23 | 480 | 15.30 ± 6.65 | 48 | 29.80 ± 8.44 | <0.01 |
| RAVLT | 280 | 44.83 ± 9.60 | 483 | 36.16 ± 10.86 | 47 | 22.32 ± 7.84 | <0.01 |
| FAQ | 281 | 0.17 ± 0.66 | 481 | 2.85 ± 3.99 | 48 | 12.6 ± 7.14 | <0.01 |
| Hippocampus (mm3) | 257 | 7344 ± 895 | 422 | 6996 ± 1126 | 39 | 5757 ± 948 | <0.01 |
| Middle Temporal (mm3) | 257 | 20298 ± 2600 | 422 | 20186 ± 2735 | 39 | 17776 ± 3230 | <0.01 |
| Entorhinal (mm3) | 257 | 3803 ± 650 | 422 | 3610 ± 723 | 39 | 2919 ± 705 | <0.01 |
| CMRgl | 207 | 6.55 ± 0.55 | 406 | 6.32 ± 0.64 | 47 | 5.30 ± 0.72 | <0.01 |
| SUVR | 152 | 1.12 ± 0.19 | 323 | 1.20 ± 0.22 | 46 | 1.39 ± 0.22 | <0.01 |
NC, normal cognition; MCI, mild cognition impairment; AD, Alzheimer’s disease; CDR-SB, Clinical Dementia Rating sum of boxes; ADAS-cog, Alzheimer’s disease Assessment Scale Cognition; MMSE, Mini-Mental State Exam; RAVLT, Rey Auditory Verbal Learning Test; FAQ, Functional Activities Questionnaire; CMRgl, Cerebral Metabolism Rate for glucose measured with fluorodeoxyglucose-positron emission tomography (FDG-PET). SUVR, florbetapir standard uptake value ratios on amyloid imaging.
*P values for continuous variables are from one-way analysis of variance (ANOVA). P values for categorical data are from chi square test.
Data are given as mean ± standard deviation unless otherwise indicated.